| Inventor | Institute |
|---|---|
| Louisa Nelson and Stephen S. Taylor | University of Manchester |
| SKU: | 161893 |
|---|---|
| Product description: | The Taylor lab Ovarian Cancer Models (OCMs) are patient-derived tumour cell cultures, unfettered by contaminating, genetically normal stromal cells and the microenvironment. OCMs display the hallmark characteristics of HGSOC and retain the unique molecular features of the original tumour. OCMs have extensive proliferative potential, enabling high-resolution cell biology and drug-sensitivity profiling on tumour cells ‘close to the patient’, i.e. without extensive culture and genetic drift. OCMs are clinically annotated, and have been extensively characterised with associated data sets being publicly available (including multi-omics data e.g. exome and RNA sequencing, and single-cell karyotyping). OCMs can also be used to generate PDX, thus enabling in vivo studies of novel therapies. Collectively, this living biobank represents comprehensive platform for basic research and drug development projects (see PMID: 37592171 for a review) |
| Gender: | Female |
| CRISPR: | No |
| Production details: | To establish cultures, red blood cells were lysed, the remaining cellular fraction harvested by centrifugation, disaggregated if necessary then plated in OCMI media. Serial passaging and selective detachment eliminated white blood cells and yielded separate tumour and stromal fractions. |
| Model description: | FIGO 3A; Ascites; BRCA1 mutation (c.3268C>T; [p.Gln1090Ter]; BRCA2 mutation (c.4725C>G [p.Asp1575Glu]); TP53 mutation (p.R248Q) |
| Cat. #: | 161893 |
|---|---|
| Provenance and Ownership: | The OCM.191 is owned by Cancer Research UK. CancerTools supplies the OCM.191 under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing OCM.191 directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Cancer types: | Ovarian cancer |
| Research Fields: | Cancer |
| Organism: | Human |
| Tissue: | Ovary. NOTE: The precursor of a substantial proportion of HGSOC is likely to be serous tubal intraepithelial carcinoma in the fimbriae of the fallopian tubes |
| Gender: | Female |
| Morphology: | Epithelial |
| Growth properties: | Adherent |
| Primary citation: | Bethany M Barnes et al. 2021. Genome Med. 1,13(1):140. PMID: 34470661 |
| Initial handling information: | Primaria™ Tissue Culture Flasks |
|---|---|
| Format: | Frozen |
| Storage conditions: | Liquid nitrogen (1/2 T75 ISO) |
| Shipping conditions: | Dry ice |
| Growth medium: | OCMI (PMID: 26080861; 32054838) + 5% hyclone FBS |
| Subculture routine: | Split sub-confluent cultures (~90%) 1:2 using 0.25% trypsin. Limit trypsin incubation to 3 mins max, multiple applications of trypsin may be required to remove all the cells from the flask. Trypsin should be neutralised using DMEM containing 20% FBS |
| Temperature: | 37° C |
| Atmosphere: | 5% CO2 & 5% O2 |
| Storage medium: | Bambanker freezing solution |
| Mycoplasma free: | Yes |
| Biosafety level: | 2 |
| References: |
Bethany M Barnes et al. 2021. Genome Med. 1,13(1):140. PMID: 34470661 Camilla Coulson-Gilmer et al. 2021. J Exp Clin Cancer Res. 16,40(1):323. PMID: 34656146 Anya Golder et al. 2022. NAR Cancer. 12,4(4):zcac036. PMID: 36381271 |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.